GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026

(Rs. in Lakhs)

	Particulars	3 months ended 30.06.2026 (Unaudited)	Preceeding 3 months ended 31.03.2026 (Unaudited) (Refer note 2)	Corresponding 3 months ended 30.06.2025 (Unaudited)	Year ended 31.03.2026 (Audited)
	Income				
1	Revenue from operations	92442	98915	80483	379020
2	Other income (Refer Note 3)	6163	3571	4376	14256
3	**Total Income (1+2)**	**98605**	**102486**	**84859**	**393276**
	Expenses				
	(a) Cost of materials consumed	5987	10147	12143	40007
	(b) Purchases of stock-in-trade	37862	22839	23207	91044
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(12204)	656	(6553)	1350
	(d) Employee benefits expense	15904	16475	15257	60725
	(e) Finance costs	97	61	42	273
	(f) Depreciation and amortisation expense	1584	1317	1552	6644
	(g) Other expenses	15577	14079	11354	55874
4	**Total expenses**	**64807**	**65574**	**57002**	**255917**
5	**Profit before exceptional items and tax (3-4)**	**33798**	**36912**	**27857**	**137359**
6	Exceptional items (credit) (Refer Note 4)	-	-	-	264
7	**Profit before tax (5+6)**	**33798**	**36912**	**27857**	**137623**
8	Tax expense				
	(a) Current tax	8135	8724	7385	35495
	(b) Deferred tax	330	694	2	946
9	**Profit for the period/year (7-8)**	**25333**	**27494**	**20470**	**101182**

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026


(Rs. in Lakhs)

	Particulars	3 months ended 30.06.2026 (Unaudited)	Preceeding 3 months ended 31.03.2026 (Unaudited) (Refer note 2)	Corresponding 3 months ended 30.06.2025 (Unaudited)	Year ended 31.03.2026 (Audited)
10	Other comprehensive loss				
	(i) Items that will not be reclassified to profit or loss	-	(1827)	-	(998)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	453	-	244
11	**Total comprehensive income for the period (9+10)**	**25333**	**26120**	**20470**	**100428**
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941
	Other equity				207177
	Earnings per share (EPS) (of Rs. 10 each)				
	Basic and diluted EPS before Exceptional items (Rs.)	14.95	16.23	12.08	59.59
	Basic and diluted EPS after Exceptional items (Rs.)	14.95	16.23	12.08	59.73
		Not Annualised			

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 03rd August 2026. The Statutory auditors have carried out a limited review of the standalone financial results for the quarter ended 30th June 2026.
2. The figures for the 3 months ended 31st March 2026 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year ended 31st March 2026.
3. Other income for the quarter ended 30th June 2026 includes Rs. 1800 lakhs on account of dividend received from Biddle Sawyer Limited, the 100% subsidiary.
4. Exceptional items credit for the year ended 31st March 2026 of Rs. 264 lakhs is on account of profit on sale of surplus residential properties.
5. Final dividend of Rs. 57 per equity share for the year ended 31st March 2026 had been approved by the shareholders in the Annual General meeting held on 30th June 2026.
6. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

By Order of the Board



Bhushan Akshikar
Managing Director
DIN: 09112346

03rd August 2026